NCT06787846View on ClinicalTrials.gov

EFFICACY and TOLERABILITY of TESTED FORMULA VS. HYDROQUINONE 4% in the TREATMENT of FACIAL MELASMA

NACompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

March 12, 2024

Study Completion Date

March 12, 2024

Conditions
Melasma
Interventions
OTHER

Experimental: Group TP

Serum : Application full face, twice daily, in the morning and at bedtime for 4 months and application Tinted sunscreen SPF 50+, twice a day

DRUG

Active Comparator: Group HQ: Hydroquinone 4%

Cream : Application all over the face once a day (at bedtime) and Tinted sunscreen SPF 50+, twice a day

Trial Locations (1)

Unknown

CIDP, Rio de Janeiro

Sponsors
All Listed Sponsors
lead

Cosmetique Active International

INDUSTRY

NCT06787846 - EFFICACY and TOLERABILITY of TESTED FORMULA VS. HYDROQUINONE 4% in the TREATMENT of FACIAL MELASMA | Biotech Hunter | Biotech Hunter